We narrowed to 9,424 results for: try

1. pDONR221-SLC8B1_STOP

   Plasmid

   #161364

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC8B1 (SLC8B1 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

2. pDONR221-SLC7A14_STOP

   Plasmid

   #161339

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC7A14 (SLC7A14 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

3. pDONR221-SLC41A3_STOP

   Plasmid

   #161332

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC41A3 (SLC41A3 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

4. pDONR221-SLC9C2_STOP

   Plasmid

   #161330

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC9C2 (SLC9A11 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

5. pDONR221-SLC29A2_STOP

   Plasmid

   #161305

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC29A2 (SLC29A2 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

6. pDONR221-SLC31A2_STOP

   Plasmid

   #161290

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC31A2 (SLC31A2 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

7. pDONR221-SLC38A6_STOP

   Plasmid

   #161272

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC38A6 (SLC38A6 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

8. pDONR221-SLC35B1_STOP

   Plasmid

   #161265

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC35B1 (SLC35B1 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

9. pDONR221-SLC2A5_STOP

   Plasmid

   #161256

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC2A5 (SLC2A5 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   Sept. 15, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

10. pDONR221-SLC2A10_STOP

    Plasmid

    #161257

    Purpose

    Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

    Depositor

    Giulio Superti-Furga, RESOLUTE Consortium

    Article

    Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

    Insert

    SLC2A10 (SLC2A10 Human)
    

    Use

    Tags

    Expression

    Mammalian

    Mutation

    Promoter

    Available since

    Sept. 15, 2021

    Availability

    Industry, Academic Institutions, and Nonprofits

    

    Enlarge